TTX — Tetratherix Share Price
Last trade - 00:00- AU$251.66m
- AU$260.48m
- 27
- 96
- 73
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | -7,410.43 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tetratherix Limited is an Australia-based company, which has developed a bio stealth fluid matrix that evolves regenerative medicine. The Company's biomaterial platform is built with polymer programming akin to Medical Lego to form implantable products to solve a range of clinical problems. The material is an injectable fluid to avoid causing damage to the body during its application. Upon injection, triggered by physiological temperature, a 3D matrix is formed that physically integrates and adheres to the target tissue. Tegenix and TegenEOS products are developed as a carrier designed to be mixed with a broad array of bone graft materials (BGMs) for dental, oral and orthopedic applications. TetraDerm products can be used in any surgical incision site to reduce scarring. Tutelix products are intended for use as a spacer to reduce side effects from radiation therapy in prostate cancer. It has established its manufacturing center in Sydney, featuring a cleanroom production facility.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 20th, 2015
- Public Since
- June 30th, 2025
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 50,331,637
- Address
- Unit 29 34-36 Ralph Street, Sydney, ALEXANDRIA, 2015
- Web
- https://tetratherix.com/
- Phone
- Auditors
- Nexia Sydney Audit Pty Limited
Similar to TTX
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 05:39 UTC, shares in Tetratherix are trading at AU$5.00. This share price information is delayed by 15 minutes.
Shares in Tetratherix last closed at AU$5.00 and the price had moved by over the past 365 days. In terms of relative price strength the Tetratherix share price has matched the ASX All Ordinaries Index by over the past year.
The overall consensus recommendation for Tetratherix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreTetratherix does not currently pay a dividend.
Tetratherix does not currently pay a dividend.
Tetratherix does not currently pay a dividend.
To buy shares in Tetratherix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$5.00, shares in Tetratherix had a market capitalisation of AU$251.66m.
Here are the trading details for Tetratherix:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: TTX
Based on an overall assessment of its quality, value and momentum Tetratherix is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tetratherix. Over the past six months, its share price has matched the ASX All Ordinaries Index by .
As of the last closing price of AU$5.00, shares in Tetratherix were trading +22.97% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Tetratherix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$5.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Tetratherix's directors